Comment on

• Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

  Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Doody RS, et al. N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889. N Engl J Med. 2014. PMID: 24450890 Clinical Trial.
• Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

  Laske C. Laske C. N Engl J Med. 2014 Apr 10;370(15):1459. doi: 10.1056/NEJMc1402193. N Engl J Med. 2014. PMID: 24716688 No abstract available.
• Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

  de la Torre JC. de la Torre JC. N Engl J Med. 2014 Apr 10;370(15):1459-60. doi: 10.1056/NEJMc1402193. N Engl J Med. 2014. PMID: 24716689 No abstract available.